Better Health for All

Genprex is a clinical-stage gene therapy company entirely focused on developing life-changing therapies for cancer and diabetes, targeting large patient populations with limited treatment options.

Its lead product candidate, Reqorsa® Gene Therapy, is in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and GPX-002 is being developed for Type 1 and Type 2 diabetes. The company's entire business model and R&D are dedicated to these health-improving gene therapies, indicating 100% of its capital allocation is aimed at improving health outcomes. All lung cancer clinical programs have received Fast Track Designation from the FDA, and the SCLC program also received an FDA Orphan Drug Designation. The company conducts open-label, multi-center Phase 1/2 clinical trials, and is thankful to patients and investigators, with data from one trial published in *Clinical Lung Cancer*.

Fair Money & Economic Opportunity

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes.

The provided articles detail its clinical trials, regulatory designations, corporate structure, and code of conduct. There is no evidence in any of the articles to suggest that Genprex, Inc. engages in financial services such as lending, insurance, or wealth management. Therefore, no specific data points are available to assess the company against any of the KPIs related to Fair Money & Economic Opportunity, and all KPIs are omitted.

Fair Pay & Worker Respect

No specific, quantitative data points were found across the provided articles to assess Genprex, Inc. against the Fair Pay & Worker Respect KPIs. Information regarding living wage coverage, CEO-to-median employee pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce is not available in the evidence provided.

While executive compensation is detailed, median employee compensation is not, preventing the calculation of a pay ratio. Regulatory compliance issues mentioned relate to Nasdaq listing requirements, not labor law or human rights violations.

Honest & Fair Business

Genprex, Inc. has a Code of Business Conduct and Ethics that prohibits retaliation against employees who report suspected violations.

A toll-free compliance hotline (1-888-958-6550) and an email address (compliance@Genprex.com) are provided for anonymous submissions, with the Chief Financial Officer serving as the Compliance Officer and the Audit Committee overseeing compliance programs. However, there is no evidence regarding the independence of investigation processes or the effectiveness of the policy. The company also has an anti-corruption policy that references the Foreign Corrupt Practices Act, U.S. Embargoes, U.S. Export Controls, and Antiboycott Regulations, requiring accurate books of account. Specifics on training frequency, risk assessments, or third-party monitoring are not provided. For board independence, the Nominating and Corporate Governance Committee is responsible for assessing director independence, including whether a majority of the Board continues to be independent according to Nasdaq requirements. The Compensation Committee and Nominating and Corporate Governance Committee charters state their members must meet Nasdaq independence requirements.

Kind to Animals

Genprex uses animal models, specifically mice and non-human primates, in its preclinical studies for gene therapy candidates like GPX-002 for diabetes.

The company does not explicitly mention the use of alternative testing methods beyond animal models. The provided articles do not state any formal animal testing policy.

Planet-Friendly Business

The company reported zero cases of non-compliance with regulatory codes concerning products and services for the year ended December 31, 2022.

It also monitors compliance with DGS India Order No 5 / 2019, HKC - IMO MEPC.269(68): 2015, and (EU) 1257/2013 Regulation on ship recycling.

Respect for Cultures & Communities

The provided articles consist of corporate governance documents, specifically an Audit Committee Charter, Compensation Committee Charter, and a Code of Business Conduct and Ethics.

These documents outline internal policies and procedures but do not contain any specific, concrete data points or performance metrics related to Genprex, Inc.'s respect for cultures and communities, or any of the defined KPIs in the rubric. Therefore, no KPIs can be scored based on the available evidence.

Safe & Smart Tech

Genprex reported no material or immaterial cyber incidents in its 2025 10-K filing, indicating no documented data breaches or unauthorized data use.

The company maintains a SOC-certified cybersecurity risk management program and states compliance with applicable legal requirements. It implements multi-factor authentication, and its 2025 10-K indicates MFA is available for 50-65% of services. Regular cybersecurity training is provided for all employees, and internal audits and continuous monitoring are conducted for vulnerability management and security testing.